Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis

Nascimento, José Carlos Rodrigues; Pereira, Lianna Cavalcante; Rêgo, Juliana Magalhães C; Dias, Ronaldo Pereira; Silva, Paulo Goberlânio B; Sobrinho, Silvio Alencar C; Coelho, Gustavo; Brasil, Ivelise Regina Canito; Oliveira-Filho, Edmilson F.; Owen, James S.; Toniutto, Pierluigi; Oriá, Reinaldo B.

doi:10.3748/wjg.v27.i11.1064

Cited by 5 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Innes et al found that rs429358 of APOE is associated with a decreased risk of developing HCC in patients with liver cirrhosis (Innes et al, 2022). The E4 allele of APOE can function as a protective factor in reducing inflammation and liver fibrosis in HCV-infected patients, which may decrease the risk of liver cancer (Nascimento et al, 2021).…”

Section: Liver Cancermentioning

confidence: 99%

Apolipoproteins: New players in cancers

Chen²,

Ma³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Apolipoproteins (APOs), the primary protein moiety of lipoproteins, are known for their crucial role in lipid traffic and metabolism. Despite extensive exploration of APOs in cardiovascular diseases, their roles in cancers did not attract enough attention. Recently, research focusing on the roles of APOs in cancers has flourished. Multiple studies demonstrate the interaction of APOs with classical pathways of tumorigenesis. Besides, the dysregulation of APOs may indicate cancer occurrence and progression, thus serving as potential biomarkers for cancer patients. Herein, we summarize the mechanisms of APOs involved in the development of various cancers, their applications as cancer biomarkers and their genetic polymorphism associated with cancer risk. Additionally, we also discuss the potential anti-cancer therapies by virtue of APOs. The comprehensive review of APOs in cancers may advance the understanding of the roles of APOs in cancers and their potential mechanisms. We hope that it will provide novel clues and new therapeutic strategies for cancers.

show abstract

Section: Liver Cancermentioning

confidence: 99%

Apolipoproteins: New players in cancers

Chen²,

Ma³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Previous research supports that apoE4 protects liver disease progression in hepatitis C virus (HCV)-induced liver injury ( 14 ). However, current evidence points to a greater risk for worse COVID-19 in patients carrying this allele, suggesting an ambiguous effect of APOE.…”

Section: Introductionmentioning

confidence: 95%

Risk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4

et al. 2022

View full text Add to dashboard Cite

“…Hence, a decrease in ApoE will result in a drop in HDL levels and an increase in LDL levels, which will exacerbate the circumstances of the liver and may lead to hepatic fibrosis. 37,38…”

Section: Apolipoproteinmentioning

confidence: 99%

Exploring Traditional and Novel Diagnostic Biomarkers for Liver Fibrosis: A Comprehensive Review

Janve,

Kakadiya

2024

J. Young Pharm.

View full text Add to dashboard Cite

Liver fibrosis is a widespread health issue brought on by a number of causes. A disease's early diagnosis is crucial for improved patient management. Different causes of persistent liver damage can result in hepatic fibrosis. One of the most important steps in determining the disease's severity is determining the degree of liver fibrosis. A disease's early diagnosis is crucial for improved patient management. There are various traditional biomarkers present for diagnosing various stages of liver fibrosis, but these traditional biomarkers have certain limitations. Liver fibrosis having low specificity (ability to determine the etiology) and low sensitivity. In medical practice, test for liver fibrosis have limited usefulness (distinguish intermediate stages). A liver biopsy is a gold standard for evaluating the stage of hepatic fibrosis, despite the fact that it has many disadvantages. Over the past ten years, several noninvasive new markers for identifying the stage of hepatic fibrosis have been created. Some are comparable to liver biopsy and have solid validation. This article aimed that Novel diagnostic biomarkers may prove to be very helpful in the near future for identifying the stages of liver fibrosis and may be just as significant as liver biopsies in doing so.

show abstract

Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis

Cited by 5 publications

References 32 publications

Apolipoproteins: New players in cancers

Apolipoproteins: New players in cancers

Risk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4

Exploring Traditional and Novel Diagnostic Biomarkers for Liver Fibrosis: A Comprehensive Review

Contact Info

Product

Resources

About